Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma
AssigneeAcetylon Pharmaceuticals, Inc.
InventorsMin Yang, David Lee Tamang, Simon Stewart Jones
Life of this patent
Estimating the term…
Abstract
The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker RNAs for multiple myeloma. The invention also relates to a kit for determining the treatment efficiency of a HDAC6 inhibitor, and a kit for identifying a histone deacetylase 6 (HDAC6) inhibitor. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.
Claims25
A kit for determining the treatment efficiency of a histone deacetylase 6 (HDAC6) inhibitor in a subject having multiple myeloma comprising:
- a detection agent that specifically binds to a HDAC6 biomarker RNA (ribonucleic acid) selected from the group consisting of SEQ ID NOs:
- 1-27;
- and
- instructions for measuring the expression level of a HDAC6 biomarker RNA comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 1-27.
A kit for identifying a histone deacetylase 6 (HDAC6) inhibitor that is useful in the treatment of multiple myeloma comprising:
- a multiple myeloma cell or a bone marrow stromal cell;
- a detection agent that specifically binds to a HDAC6 biomarker RNA (ribonucleic acid) selected from the group consisting of SEQ ID NOs:
- 1-27;
- and
- instructions for measuring the expression level of a HDAC6 biomarker RNA comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 1-27.
A method for monitoring the treatment efficiency of a histone deacetylase 6 (HDAC6) inhibitor in a subject comprising:
- a) administering a therapeutically effective amount of an HDAC6 inhibitor to a subject;
- b) taking a biological sample from the subject;
- c) determining the amount of a HDAC6 biomarker RNA (ribonucleic acid) comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 1-27 in the sample;
- and
- d) concluding that the HDAC6 treatment is efficient if a HDAC6 biomarker RNA comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 1-11, 24, and 26-27 is down-regulated, and/or if a HDAC6 biomarker RNA comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 12-23 and 25 is up-regulated.
A biomarker ribonucleic acid (RNA) comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 1-27.
Dependencies are inferred from the claim text.